$COSM Eurozone ExpansionThe recent acquisition of pharmaceutical laboratories CANA S.A. (CANA) by Cosmos Health Inc. (NASDAQ: COSM) could be seen as a bullish indicator regarding the company’s long-term prosperity. As a result of this development, the company now controls a 54 thousand square ft. manufacturing facility in Athens and multiple functioning product lines that will assist in its vertical integration efforts. In this way, the company would be able to improve its profitability prospects due to potential cost reductions since the company manufactures its products with a 3rd party. For this reason, COSM stock could be a worthy long-term investment given that it now controls a drug manufacturer, wholesale pharmacies, and retail pharmacies.
COSM Fundamentals
After a long string of acquisitions, COSM took a huge step towards vertical integration by purchasing CANA which is a Greek drug manufacturer. Thanks to this purchase, COSM could now boost the performance of its other subsidiaries by integrating CANA with other retail and distribution-oriented subsidiaries like Docpharm, Skypharm, and Cosmopharm.
COSM acquired CANA at a bargain price of $1.67 million in cash and stock which could be extremely cheap taking into consideration that CANA is not a run-of-the-mill pharmaceutical company. Additionally, members of CANA’s old management team accepted COSM shares at a price of $17.25 per share – indicating that they believe the COSM stock price should increase as a result of this transaction.
One of the potential upsides of this acquisition is the possibility of obtaining lucrative contracts with multinational institutions as a result of COSM’s new manufacturing capabilities. This possibility is likely given CANA’s reputation and previous partnerships with well-established players like AstraZeneca, Janssen, P&G, and Nestle. These partnerships indicate that these multinational giants trusted CANA’s capabilities which in turn means that the quality of CANA’s work is enough to satisfy these industry leaders.
Meanwhile, the true value of this acquisition could only be grasped when taking into consideration the incorporation of CANA with COSM’s other subsidiaries. Normally, pharmaceutical manufacturers would sell their drugs to a pharmaceutical wholesaler which would then sell the drugs to pharmaceutical retailers after bumping up the price to make a profit. That said, in a vertically integrated system like COSM’s, the manufacturer and retailer serve a single entity which means that the wholesaler could sell their drugs directly to the retailer without a wholesaler present.
On that note, CANA already has a portfolio of owned brands including pharmaceuticals, dermocosmetics such as Eleon Cosmetics, antiseptics such as C-Sept, food supplements, as well as an infant care organic product line, Biobebe. In this way, COSM may offer these products at its wholesale and retail pharmacies at a competitive price due to vertical integration which may allow these products to gain market share as they could be cheaper than their competitors.
Since CANA has an ISO certification and a European Good Manufacturing Practices (GMP), license it is capable of trading effortlessly in the Eurozone. This means that CANA could supply Docpharm with drugs at a discounted price via vertical integration and COSM would still reap substantial revenues due to the lack of an intermediary trader. If COSM utilizes this potential partnership to its fullest potential, Docpharm could provide the German market, which is already extremely competitive, with OTC drugs at a lower rate than most retailers resulting in an increase in demand and greater revenue.
Additionally, COSM’s wholesalers Cosmopharm and Decahedron may benefit from CANA’s acquisition by having specialized production lines that offer high-demand products. It is also worth noting that discounted prices for COSM’s wholesalers is also a possibility since both parties fall under the COSM banner.
That said, an additional positive outcome that is likely is that this partnership could lead to cost reduction due to the termination or reduction of outsourcing production. Currently, COSM is in an agreement with Doc Pharmae for the development and manufacturing of pharmaceutical products and nutritional supplements. Following the acquisition of CANA, COSM could now start producing SkyPharm’s Sky Premium Life products at CANA’s facility which might result in cost savings. Having said that, there is no publicly available data to calculate the expected cost reductions.
Technical Analysis
COSM stock is in a neutral trend and is trading in a sideways channel between its support at $2.98 and its resistance at $3.65. Looking at the indicators, the stock is trading below the 200, 50, and 21 MAs which is a bearish indication. Meanwhile, the RSI is neutral at 38 and the MACD is approaching a bullish crossover.
Despite the bearish indicators, COSM’s fundamentals may be solid following the recent acquisition of CANA since it could boost revenue and reduce costs due to vertical integration. Given that the stock has a strong support at $2.98, bullish investors could find retests of this support an opportunity to go long on the stock in anticipation of more details regarding vertical integration which may start showing in the company’s 2023 annual report.
COSM Forecast
With the acquisition of CANA, COSM’s subsidiaries have the potential to thrive through vertical integration which is extremely promising for the stock. This is mainly due to the potential revenue growth as a result of gaining market share thanks to lower prices and the possible cost savings since the company is currently outsourcing production of SkyPharm’s Sky Premium Life products. While the impacts of this acquisition may not show before the company’s 2023 annual report, COSM stock could be a bargain at current levels as it is trading near a strong support.
COSM trade ideas
$COSM Eurozone ExpansionExpansions can be extremely beneficial for a business and that is the case for the pharmaceutical wholesale provider – Cosmos Health Inc. (NASDAQ: COSM). After adding a new German drug wholesaler under its umbrella, COSM appears to be on track to extend its reach throughout the whole European market. As this recent acquisition is set to boost the company’s revenues by 70%, the COSM stock price could be set to increase in the near term.
COSM Fundamentals
After adding Docpharm to its portfolio of subsidiaries, COSM now controls 4 subsidiaries within Europe where 2 subsidiaries are based in Greece – Skypharm and Cosmopharm, DHS in the UK, and finally Docpharm in Germany. All of these subsidiaries play a critical role in COSM’s growth since they extend its reach throughout the entirety of Europe.
At the same time, Docpharm’s addition has a substantial strategic benefit for COSM since Germany has the largest pharmaceutical market in Europe. With this in mind, the German market accounts for a 5.9% share of the global pharmaceutical market. If COSM is able to gain a fraction of this market, it could account for a major increase in revenue.
Europe’s pharmaceutical market is unique in that it is governed by a supranational institution that regulates drug approval throughout the continent which means that COSM’s subsidiaries are not shackled by border restrictions. In this way, Docpharm and the Greek wholesalers can freely trade with pharmacies in neighboring countries. That said, the Greek wholesalers provide COSM with access to the Balkans while Docpharm provides access to Western Europe.
Through these subsidiaries, COSM has a solid grip on the European pharmaceutical market which was worth $282.5 billion in 2020 and is expected to grow at a CAGR of 5.4% through 2028. As these subsidiaries develop they are likely to grow their reach and envelope more of Europe’s gargantuan pharmaceutical market. For this reason, COSM stock could be a bargain at its current PPS.
COSM Financials
COSM’s balance sheet is extremely promising. According to its Q1 report its assets remained at $68 million QoQ, which said its cash, and cash equivalents decreased from $20.7 million to $12 million. This might seem like a significant loss if not for COSM’s stark drop in liabilities as current liabilities dropped from $21.7 million to $18.5 million, and total liabilities decreased from $28.3 million to $23.6 million.
COSM revenues decreased slightly YoY from $13 million to $12.3 million. That said, its operating expenses jumped from $1.6 million to $3.6 million. In this way, COSM reported a net loss of $459.8 thousand compared to a net income of $203.3 thousand in Q1 2022.
Technical Analysis
COSM stock is in a neutral trend with the stock trading in a sideways channel between the support at $2.94 and the resistance at $3.65. Looking at the indicators, COSM stock is below the 200, 50, and 21 MAs which are bearish indications. Meanwhile, the RSI is neutral at 37 and the MACD is neutral.
As for the fundamentals, COSM recently witnessed a catalyst in its acquisition of Docpharm which is expected to boost its revenues by 70%. Given that this acquisition extends the company’s reach across Europe, the COSM stock could be poised to appreciate to reflect Docpharm’s added value.
COSM Forecast
COSM Stock may surge due to increased revenue brought about by its purchase of Docpharm. As a result of the acquisition, COSM now has an entry point into Western Europe that compliments COSM’s Greek subsidiaries. As is, COSM is expanding its reach into Europe’s $282 Billion dollar pharmaceutical market, and as a result, COSM stock may surge due to the expected surge in revenue.
COSM might be on a 300% runBased on the indicators I'm using, the possibility of > 300% homerun seems to be very possible. I set my trailing stop to 5% and will sell 50% as soon as the first target of 100% is reached. The remaining 50% I let run to $12.50 with a 3% trailing stop. I will buy in again at $10.38 and let it run up to the $20 mark with a 3% trailing stop.
Of course I will monitor the chart during the time and see if it performs as projected and adjust accordingly.
COSM COSM = the theory of precedent and cyclicality next to a short interest of 600% tells us only one thing .. that if there will be no RS ..reversal split .. this is the time to have a perfect golden triangle .. from 0.30 to 1$ there is about 90% probability, the remainder brings it to 2-3$ .. As a risk return I think it is an excellent return
Come on Trump.. always
$COSM Short Squeeze Stocks To Buy NowAfter soaring more than 800% over the past few weeks, Cosmos Holdings Inc. (NASDAQ: COSM) is considered to be one of this year’s hottest short squeeze plays. As an international healthcare group, COSM is mainly focused on identifying, acquiring, developing, and commercializing different medications. While the company’s business line could prove to be profitable in the future, COSM stock has been witnessing rising short selling activity over the past months – sending the stock to new all-time lows. With the stock gaining investors’ attention thanks to its short squeeze potential, COSM stock could be one to watch over the coming weeks.
COSM Fundamentals
Operating through 3 subsidiaries in Greece and the UK, COSM specializes in the wholesale of pharmaceutical products across Europe. To facilitate its business, COSM has a wide network of more than 160 clients and vendors throughout Europe, Vietnam, and the UAE. Through this network, COSM is able to develop and distribute its own proprietary line of nutraceuticals, branded generics, and OTC pharmaceuticals. At the same time, COSM has its own distribution network that allows the company to provide local markets with its products as well as promoting its own proprietary lines. Moreover, COSM has a number of strategic relationships and market synergies with other global pharma companies to facilitate the production of its products. Thanks to this structure, COSM stock could be a profitable long-term hold as the company continues expanding its business.
With this in mind, COSM currently has two proprietary premium nutraceutical brands – Mediterranation and Sky Premium Life. These brands are high-quality nutritional supplements brands including a wide range of vitamins, minerals, herbs, and unique formulas. Given that the European nutraceutical market is expected to pass $100 billion by 2027, COSM’s products could position the company for substantial growth in the future as it continues to expand its nutraceuticals’ global reach.
On that note, COSM entered a partnership with airline company Iberia to offer its Sky Premium Life brand through Ronda in-flight magazine. In this way, more than 10 million annual passengers would have access to COSM’s products which could be reflected in the company’s revenues in the future. Given that Ronda’s readership has a strong purchasing power with 81% above the age of 35 and 72% having higher education degrees, COSM could witness a major spike in sales thanks to this deal.
Looking to expand its products’ reach globally, COSM entered into an LOI with Smart for Life, Inc. (NASDAQ: SMFL) for a strategic co-venture agreement. According to this deal, both companies are set to cross market each other’s products in their respective markets. In this way, SMFL could benefit from COSM’s distribution capabilities in Europe to bolster its revenues. Meanwhile, this deal could allow COSM to realize substantial revenues from its proprietary brands – Sky Premium Life and Mediterranation – by distributing them in the US. Considering the growing interest in nutraceuticals from US citizens following the pandemic, COSM could realize record sales from its brands.
In addition to expanding into new markets, COSM is looking to enter new segments in the healthcare industry – especially the telehealth market. For this reason, COSM entered into an LOI with American International Holdings Corp (OTC: AMIH) to acquire its subsidiary – ZipDoctor Inc. As a DTC subscription-based telehealth platform, ZipDoctor provides its customers affordable and unlimited access to certified physicians and licensed mental and behavioral health counselors and therapists. Given the potential of this platform, COSM intends to expand its services to include the ability to speak to a doctor to seek additional treatments like men’s and women’s health and weight loss. Since this acquisition is yet to be finalized, COSM stock could witness a run when the acquisition is completed.
At the same time, COSM is working to expand its product portfolio as it entered the development phase for CCX0722 for obesity and weight management in collaboration with Cloudpharm. This treatment is based on the effectiveness of biocompatible 3D spatial fillers from natural ingredients. On that note, spatial fillers are able to absorb and retain large amounts of water and biological fluids. Based on this, administration of CCX0722 could reduce food intake as it is able to increase satiety and reduce appetite. Considering the unmet need for such a product, CCX0722 could witness high demand once it is launched into the market. However, this step could take significant time as COSM plans to initiate clinical intervention in Q4 2023. With the company looking to penetrate this underserved market, COSM stock could be poised for a significant boost in its PPS in the long-term.
Meanwhile, COSM also has agreements to market and distribute other products in select locations. With this in mind, the company recently entered into an agreement to market and distribute Nickelodeon’s SpongeBob and PAW Patrol kids’ vitamins in Greece and Cyprus. Considering the popularity of these characters in Greece and Cyprus, COSM is witnessing high demand for these products from large chain retailers and pharmacies. In this way, COSM is aiming for these products to reach 11 thousand pharmacies and 120 wholesalers in Greece in addition to 780 pharmacies in Cyprus. Given the major marketing support from Nickelodeon, this deal could position COSM to receive a major boost in revenues in the coming quarters.
Despite the company’s promising fundamentals, COSM stock is gaining momentum thanks to its ongoing short squeeze which has seen the stock climb from $.07 to nearly $.85 in the span of 3 trading weeks. With this in mind, COSM remains witnessing an increasing short selling activity with its short interest rate at 16% with 20% of the float on loan. While these numbers could be insignificant for a short squeeze to occur, COSM’s cost to borrow is extremely high at 205% and there are no shares available to short. As a result, COSM stock has the potential to further run in the coming weeks as more investors are entering into the stock.
Considering the stock’s strong price movement lately, many investors are bullish COSM stock could break through $1 and regain compliance with the NASDAQ listing rules as the stock has been trading below $1 since April. Since the company has until January 23, 2023 to regain compliance with listing requirements, many investors are confident COSM stock will continue trading on the NASDAQ for the foreseeable future. On that note, COSM is holding its annual shareholders meeting on December 2 where shareholders will vote on a proposal providing discretion to the BOD to effect a reverse split if needed to regain compliance with the NASDAQ rules.
However, COSM could have major news on the horizon that could help the stock regain compliance without effecting a reverse split. This conviction could be thanks to the recent insider activity as the company’s CEO Grigorios Siokas purchased 12.5 million shares back in October in addition to 801.2 thousand shares this month. As these transactions highlight Siokas’ confidence in the company’s future prospects, COSM stock could be one to watch closely for a continuation of its current run.
COSM Financials
Looking into COSM’s Q3 financials, the company has $45.6 million in assets – including $312.3 thousand in cash as well as $25.2 million in accounts receivable. In Q3, COSM successfully reduced its liabilities to $40.4 million compared to $45 million at the beginning of the year. This decline is mainly fueled by the company reducing its long-term notes payable to $1 million compared to $12.3 million. Meanwhile, COSM realized $12 million in revenues – declining from $13.5 million a year ago. As for operating costs, the company reported $2.1 million – representing a decrease from $3.2 million in the same year-ago-period. In this way, COSM reported a net loss of $1.9 million.
Technical Analysis
COSM stock is currently trading at $.7725 and shows supports near .5850, .4232, and .2895. Meanwhile, the stock shows resistances near .8437 and 1.1657. As COSM failed to break through its resistance twice recently, the stock could be poised for a pullback as profit taking could take place thanks to the stock’s impressive run over the past weeks. In that case, COSM could drop near its $.58 support which could be an ideal entry for bullish investors as the stock could soar in the coming weeks thanks to the bullish sentiment surrounding it.
Accumulation is trending downwards as investors could be taking profits thanks to the stock’s parabolic run. However, the MACD is bullish to the upside. The RSI is at 75 indicating that COSM stock is currently oversold. In light of this, bullish investors could wait for the RSI to regulate for a better entry point on COSM stock. As for its share structure, COSM has an OS of 83.8 million and a float of 58.5 million.
COSM Forecast
As the company is looking to regain compliance with the NASDAQ listing requirements, COSM is one to watch as it could further run in the coming weeks given the momentum it is witnessing. Considering the stock’s significantly high cost to borrow and rising short interest, COSM stock could soar when short sellers have to cover their positions. Meanwhile, COSM could be considered a long-term investment thanks to the company’s constant efforts to expand into new markets and new segments. With the company now entering the development stage of its obesity product, COSM could be poised for long-term growth given that this segment is extremely underserved. In light of this, COSM stock could be one to buy now given its short-term and long-term potential.
$COSMCosmos Holdings Inc. operates as a vertically integrated pharmaceutical company. It offers proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter (OTC) medications, health care, baby products, medical devices, and other products through its distribution channels and e-commerce market place. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece, and the United Kingdom; and warehousing facility. It serves wholesale pharmaceutical distributors and independent retail pharmacies. The company was formerly known as Prime Estates and Developments, Inc. and changed its name to Cosmos Holdings Inc. in November 2013. Cosmos Holdings Inc. was incorporated in 2009 and is based in Chicago, Illinois.